ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESM..................*JBDM Ver 0.1.67 (18 Oct 2017) - 2999001/02694959CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120191225W173deBibliographieenBibliographyfrBibliographieEP12765178.4201203302013103120181204enenen201161471036 P20110401US2019122520195220140212201407201911132019462019052420191225201952C12Q 1/6886 20180101AFI20190412BHEP A61K 31/517 20060101ALI20190412BHEP A61K 31/58 20060101ALI20190412BHEP deBIOMARKER ZUR VORHERSAGE DES ANSPRECHENS AUF KREBSBEHANDLUNGENenBIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTSfrMARQUEURS BIOLOGIQUES POUR PRÉVOIR LA SENSIBILITÉ À DES TRAITEMENTS DU CANCERWO-A2-2008/049022US-A1- 2006 142 178US-A1- 2009 028 855US-A1- 2011 038 862Josep Tabernero ET AL: "Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor", , 9 March 2011 (2011-03-09), XP055153957, Retrieved from the Internet: URL:http://www.arraybiopharma.com/files/20 13/9810/8011/PubAttachment437.pdf [retrieved on 2014-11-19]LIN K ET AL: "79 Preclinical characterization of GDC-0068, a novel selective ATP competitive inhibitor of Akt", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 8, no. 7, 1 November 2010 (2010-11-01), page 33, XP027497767, ISSN: 1359-6349, DOI: 10.1016/S1359-6349(10)71784-5 [retrieved on 2010-11-01]MARGRITH E MATTMANN ET AL: "Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape/x-ms-", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 21, no. 9, 1 January 2011 (2011-01-01), pages 1309-1338, XP008159752, ISSN: 1354-3776, DOI: 10.1517/13543776.2011.587959A Cervantes ET AL: "Results of the First-in-human Phase I Study of GDC-0068, an Akt Inhibitor That Demonstrates Safe and Sustained Targeting of the PI3K/Akt Pathway in Patients (pts) with Advanced Solid Tumors", , no. 619 9 November 2012 (2012-11-09), XP055153817, Retrieved from the Internet: URL:http://ac.els-cdn.com/S095980491272416 4/1-s2.0-S0959804912724164-main.pdf?_tid=c f218536-6fc1-11e4-9243-00000aab0f6b&acdnat =1416384072_c6a32af2864559b484a7273ad71c8a bc [retrieved on 2014-11-19]BARNETT ET AL.: 'Identification and characterization of pleckstrin-homology-domaindependent and isoenzyme-specific Akt inhibitors' BIOCHEM. J. vol. 385, 2005, pages 399 - 408, XP055060694OKUZUMI ET AL.: 'Inhibitor Hijacking of Akt Activation' NAT. CHEM. BIOL. vol. 5, no. 7, July 2009, pages 484 - 493, XP055093045SKORSKI ET AL.: 'Transformation of hematopoietic cells by BCR/ABL requires activation of a PI- 3K/Akt-dependent pathway' EMBO J. vol. 16, no. 20, 1997, pages 6151 - 6161, XP055093052KIM ET AL.: 'Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias' BR. J. CANCER vol. 98, 2008, pages 1533 - 1535, XP055091514MAHADEVAN ET AL.: 'Discovery of a novel class of AKT pleckstrin homology domain inhibitors' MOL. CAN. THER. vol. 7, no. 9, September 2008, pages 2621 - 2632, XP0550915192014120119203410.620191015LIN, Kui1 DNA WaySouth San Francisco California 94080-4990USPUNNOOSE, Elizabeth1 DNA WaySouth San Francisco California 94080-4990USSESHAGIRI, Somasekar1 DNA WaySouth San Francisco California 94080-4990USGenentech, Inc.100129003SRB/FP69428251 DNA WaySouth San Francisco, CA 94080-4990USMewburn Ellis LLP101783151City Tower 40 Basinghall StreetLondon EC2V 5DEGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRBA20131031ME20131031US201203166220120330enWO201213574920121004201240